BioCryst’s Strong Q2 Performance and Unique Market Position Justify Buy Rating

Analyst Tazeen Ahmad of Bank of America Securities reiterated a Buy rating on BioCryst, retaining the price target of $15.00.

Tazeen Ahmad’s rating is based on BioCryst’s strong second-quarter performance, driven by impressive demand trends for Orladeyo, which exceeded market expectations. The company reported revenues of $156.8 million, surpassing both Bank of America’s and consensus estimates. This growth is attributed to a record number of new patient prescriptions and the activation of new prescribers.
Furthermore, the unique position of Orladeyo as the only oral prophylactic therapy for hereditary angioedema (HAE) on the market, with no immediate competition, supports continued growth prospects. The upcoming potential approval of Orladeyo for pediatric HAE patients presents an additional opportunity for market expansion. Additionally, the company’s strategic decisions, such as the sale of its EU franchise and the upcoming leadership transition, are expected to positively impact its financial outlook. These factors collectively justify the Buy rating with a price objective of $15.

Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, Incyte, and ACADIA Pharmaceuticals. According to TipRanks, Ahmad has an average return of -3.5% and a 48.68% success rate on recommended stocks.

In another report released yesterday, Needham also maintained a Buy rating on the stock with a $17.00 price target.